All In Biotech

NDA 020213 · Bausch and Lomb

Miochol-E

Acetylcholine Chloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Jun 17, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Sep 22, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

150

18 Phase 3, 21 recruiting

FAERS reports

98

79 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 17, 2023.

INDICATIONS AND USAGE To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 22, 1993 Original approval · Type 3 - New Dosage Form
1 products under this application
  • MIOCHOL-E · ACETYLCHOLINE CHLORIDE 20MG/VIAL · FOR SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetylcholine Chloride" as an intervention, any sponsor and status, largest first.

All 150 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • depression35
  • cough34
  • dyspnoea34
  • rhinorrhoea34
  • sinusitis34
  • sleep disorder34
  • sleep disorder due to a general medical condition34
  • therapeutic product effect incomplete34
  • anxiety33
  • asthma33
  • breast cancer33
  • chest discomfort33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20091
20102
20122
20132
20153
20162
20175
20182
20192
20205
202117
202221
202311
20244
20257
202611

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.